KeyHealth to appeal order to fund teenager’s rare-disease treatment
The Appeals Committee found KeyHealth had not shown its proposed care was an effective alternative and ordered it to fund ravulizumab in full.
#ParoxysmalNocturnalHaemoglobinuria
Services
Investment Rates
Money Market funds
Updated 2 November 2026
FAIS Ombud awards and settlements rise to R39.6m
Newsletter Subscription
Stay at the top of your game
Subscribe
